We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Regulatory compliance
The TGA monitors and enforces regulatory compliance in relation to therapeutic goods. This supports consumer protection and a fair market for industry.
Latest alerts
-
MAXMAN tablets pose a serious risk to your health and should not be taken.
-
Gold Max Blue capsules pose a serious risk to your health and should not be taken.
-
African Vigorous Max Strength poses a serious risk to your health and should not be taken.
Latest articles
-
TGA and InstantScripts reach settlement
The TGA has settled judicial review proceedings brought by InstantScripts in respect of infringement notices issued to it by the TGA. -
Sun Herbal Pty Ltd fined $18,780 for alleged unlawful supply of a complementary medicine
We have issued an infringement notice to the New South Wales based company for the alleged supply of a complementary medicine that was missing a mandatory warning statement. -
New quality standards for MDMA and psilocybine
Two new quality standards, one for MDMA and another for psilocybine, have been published.
Latest publications
-
This fact sheet is for healthcare practitioners to help understand the rules surrounding importation of cosmetic injectables.
-
This plan outlines the compliance and education priorities of the Therapeutic Goods Administration for 2024.
-
Overview of therapeutic goods advertising complaints handling and compliance for 2022-23